Synchron has announced the launch of a community-centred brain-computer interface (BCI) registry to bring patients, carers and clinicians together to learn how BCI technology is being designed to provide benefit to people with limited mobility.
Synchron’s BCI technology—primarily seen in the company’s Stentrode device—is designed to decipher the neural code of the brain and find new ways to restore motor intent to control digital devices. The Synchron BCI represents a novel approach to restoring functionality in patients with limited mobility, according to a company press release. By leveraging an individual’s blood vessels, the device is implanted in the brain without the need for invasive brain surgery.
“We are thrilled to launch our community-centred BCI registry,” said Tom Oxley, chief executive officer and founder, Synchron. “There is a grass roots movement happening with BCI. We are creating an avenue for potential users and their physicians to engage, and stay connected, while we prepare for the next stage of clinical trials.”
“BCI technology enables individuals with motor impairment to regain independence,” said principal investigator David Lacomis (University of Pittsburgh, Pittsburgh, USA). “By controlling digital devices through one’s own thoughts, BCI offers a transformative path towards performing daily tasks with greater ease and efficiency. From communication to accessing essential services online, BCI technology represents a groundbreaking frontier for individuals and their families.”
